Sudarshan Pharma Industries announced that its proposal to acquire a 9.50% equity stake in MedTherapy Biotechnology Inc., USA remains under due diligence, with confirmation and board resolution from MedTherapy pending. According to the company's latest filing under Regulation 30 of SEBI LODR Regulations, 2015, the proposed acquisition includes a 1.50% stake each by its promoters, Hemal Mehta, Chairman & Managing Director, and Sachin Mehta, Joint Managing Director, both of which are also under due diligence with pending board confirmation and resolution. The company expects to provide an update at the earliest and anticipates completion by March 31, 2027. The Mumbai-based pharma firm issued this disclosure following a previous communication dated September 5, 2026, and requested stock exchanges to record the status of these pending transactions.
As reported by Live Mint, the acquisition is part of Sudarshan Pharma's plans to enter the US market and gain access to MedTherapy's existing customer base, contracts, and distribution network. The company will finance the deal through cash consideration denominated in US dollars, with the purchase price determined based on prevailing valuation norms of MedTherapy Biotechnology. MedTherapy Biotech was founded in 2018 by experts from Harvard and former Novartis executives, operating as an end-to-end, integrated CAR-T cell CDMO with a commercial-scale GMP manufacturing facility in New Delhi, India, and a technology development center in Boston, USA. The filing clarified that the proposal has been intimated to stakeholders but is not yet finalized, with no financial figures or valuation details disclosed for the proposed stakes.
According to Live Mint, Sudarshan Pharma shares have demonstrated exceptional performance, surging 42% in 2026 to ₹39 per share and generating a 350% gain over the last three years. The stock has recovered all of its 38% decline in 2025, with retail shareholders holding a 21.2% stake in the company at the end of the June quarter. Despite near-term volatility, the shares have been closing each passing month with higher returns, rewarding shareholders handsomely. The company's latest stock performance shows +15.01% over one month and +55.38% over six months, with the stock trading at ₹39 per share as of the latest data.
